WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
Pharma & Biotech
Pharma & Biotech
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.
Pharma & Biotech
Why the SRS–Lenke–Aubin 3D classification could reshape adolescent scoliosis research
The SRS–Lenke–Aubin 3D classification brings new depth to AIS care. Find out how it could reshape surgery, planning, and clinical trial design.
Pharma & Biotech
CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.
Pharma & Biotech
What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
Pharma & Biotech
Can ALK-Abelló’s EURneffy launch shift real-world adoption of non-injectable adrenaline in EU schools?
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Pharma & Biotech
Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.
Pharma & Biotech
Tenacia’s ZTALMY launch shows new blueprint for orphan neurology drugs in China
ZTALMY gains commercial launch in China for CDKL5 seizures. Find out what this means for rare disease drug access and neurology strategy.
Pharma & Biotech
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site
Pharma & Biotech
What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.